SCHEMBL21678701

SCHEMBL21678701

CCOc1ccccc1C(=O)OC(=O)/C=C/C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
ALDH1A1 P00352 2/20 0.47
GLA P06280 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
RAB9A P51151 1/20 0.44
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 1/20 0.42
EGFR P00533 1/20 0.42
HTT P42858 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21678752 0.89 KMT2A (0.47) L3MBTL1ALDH1A1MEN1KMT2AMAPT
SCHEMBL21678783 0.88 LMNA (0.50) L3MBTL1ALDH1A1MEN1KMT2AMAPT
SCHEMBL21678774 0.84 SMN1; SMN2 (0.50) ALDH1A1GLAKMT2AESR1ESR2
Fumaric Acid SCHEMBL28397702 0.83 ALDH1A1 (0.56) HCRTR1L3MBTL1ALDH1A1GLAMEN1
SCHEMBL28992535 0.83 HCRTR1 (0.62) HCRTR1L3MBTL1ALDH1A1GLAMEN1
SCHEMBL240024 0.82 HSD17B10 (0.65) ALDH1A1KMT2AESR1ESR2MAPT
SCHEMBL6589832 0.82 HCRTR1 (0.57) HCRTR1L3MBTL1ALDH1A1GLAMEN1
SCHEMBL33469 0.81 HCAR2 (0.50) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL21678779 0.80 IRAK4 (0.53) ALDH1A1MAPTKDM4EHPGDHSD17B10
SCHEMBL1006864 0.80 HCRTR1 (0.58) HCRTR1L3MBTL1ALDH1A1GLAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2024-01-09 US claimed
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2021-06-17 US claimed
EP-3611157-A1 SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES Chongqing Neuropark Bioscience Co., Ltd. (CN) 2020-02-19 EP claimed
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2020-02-13 US claimed
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2024-01-09 US disclosed
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2021-06-17 US disclosed
EP-3611157-A1 SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES Chongqing Neuropark Bioscience Co., Ltd. (CN) 2020-02-19 EP disclosed
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) 2020-02-13 US disclosed
CN-106946701-A Salicylic acid-based fumarate derivative and application thereof in treating Parkinson's disease and other neurodegenerative diseases 杨立川 2017-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210179533-A1 SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB HCRTR1 1969/4885L3MBTL1 3743/4885ALDH1A1 249/4885
US-20200048182-A1 A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES FH, SUCNR1, SDHB HCRTR1 2015/4885L3MBTL1 3810/4885ALDH1A1 261/4885
US-11866401-B2 Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases FH, SUCNR1, SDHB HCRTR1 2093/4885L3MBTL1 3741/4885ALDH1A1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.